<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ann Transl Med</journal-id>
<journal-id journal-id-type="iso-abbrev">Ann Transl Med</journal-id>
<journal-id journal-id-type="publisher-id">ATM</journal-id>
<journal-title-group>
<journal-title>Annals of Translational Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">2305-5839</issn>
<issn pub-type="epub">2305-5847</issn>
<publisher>
<publisher-name>AME Publishing Company</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32042808</article-id>
<article-id pub-id-type="pmc">6989979</article-id>
<article-id pub-id-type="publisher-id">atm-07-23-792</article-id>
<article-id pub-id-type="doi">10.21037/atm.2019.11.53</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Emerging biomarkers in autism spectrum disorder: a systematic review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Frye</surname>
<given-names>Richard E.</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Vassall</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kaur</surname>
<given-names>Gurjot</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lewis</surname>
<given-names>Christina</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karim</surname>
<given-names>Mohammand</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rossignol</surname>
<given-names>Daniel</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<aff id="aff1"><label>1</label><institution>Barrow Neurological Institute at Phoenix Children’s Hospital</institution>, <addr-line>Phoenix, AZ</addr-line>, <country>USA</country>;</aff>
<aff id="aff2"><label>2</label>Deparment of Child Health, <institution>University of Arizona College of Medicine</institution>, <addr-line>Phoenix, AZ</addr-line>, <country>USA</country>;</aff>
<aff id="aff3"><label>3</label><institution>Rossignol Medical Center</institution>, <addr-line>Aliso Viejo, CA</addr-line>, <country>USA</country></aff>
</contrib-group>
<author-notes>
<fn id="afn1">
<p><italic>Contributions:</italic> (I) Conception and design: RE Frye; (II) Administrative support: S Vassall, G Kaur, C Lewis; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: S Vassall, G Kaur, C Lewis, M Karim; (V) Data analysis and interpretation: RE Frye, D Rossignol; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p>
</fn>
<corresp id="cor1"><italic>Correspondence to:</italic> Richard E. Frye. Barrow Neurological Institute at Phoenix Children’s Hospital, Phoenix, AZ 85016, USA. Email: <email xlink:href="rfrye@phoenixchildrens.com">rfrye@phoenixchildrens.com</email>.</corresp>
<fn fn-type="COI-statement">
<p><italic>Conflicts of Interest:</italic> Dr. Frye is funded by the National Institutes of Health, Department of Defense, and Autism Speaks and receives support from the The Turnabout for Autism and Autism Research Institute foundations and Zynerba Pharmaceuticals. The author is on the advisory boards of Iliad Neurosciences, NeuroNeeds and Cox Biosciences. Dr. Rossignol is on the advisory board of NeuroNeeds.</p>
</fn>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>12</month>
<year>2019</year>
</pub-date>
<!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
<pub-date pub-type="ppub">
<month>12</month>
<year>2019</year>
</pub-date>
<volume>7</volume>
<issue>23</issue>
<elocation-id>792</elocation-id>
<history>
<date date-type="received">
<day>28</day>
<month>10</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>11</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>2019 Annals of Translational Medicine. All rights reserved.</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder>Annals of Translational Medicine.</copyright-holder>
</permissions>
<abstract>
<p>Autism spectrum disorder (ASD) affects approximately 2% of children in the United States (US) yet its etiology is unclear and effective treatments are lacking. Therapeutic interventions are most effective if started early in life, yet diagnosis often remains delayed, partly because the diagnosis of ASD is based on identifying abnormal behaviors that may not emerge until the disorder is well established. Biomarkers that identify children at risk during the pre-symptomatic period, assist with early diagnosis, confirm behavioral observations, stratify patients into subgroups, and predict therapeutic response would be a great advance. Here we underwent a systematic review of the literature on ASD to identify promising biomarkers and rated the biomarkers in regards to a Level of Evidence and Grade of Recommendation using the Oxford Centre for Evidence-Based Medicine scale. Biomarkers identified by our review included physiological biomarkers that identify neuroimmune and metabolic abnormalities, neurological biomarkers including abnormalities in brain structure, function and neurophysiology, subtle behavioral biomarkers including atypical development of visual attention, genetic biomarkers and gastrointestinal biomarkers. Biomarkers of ASD may be found prior to birth and after diagnosis and some may predict response to specific treatments. Many promising biomarkers have been developed for ASD. However, many biomarkers are preliminary and need to be validated and their role in the diagnosis and treatment of ASD needs to be defined. It is likely that biomarkers will need to be combined to be effective to identify ASD early and guide treatment.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title>Keywords: </title>
<kwd>Autism spectrum disorder (ASD)</kwd>
<kwd>biomarkers</kwd>
<kwd>epigenetic</kwd>
<kwd>eye movement</kwd>
<kwd>folate</kwd>
<kwd>genetic</kwd>
<kwd>mitochondria</kwd>
<kwd>methylation</kwd>
<kwd>neuroimmune</kwd>
<kwd>neurophysiology</kwd>
<kwd>redox</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>